LARONDE
Laronde develops an eRNA-based therapeutic platform that is capable of indicating diverse proteins inside the body. It is persistent, non-immunogenic, allows for repeat dosing, and offers flexibility in formulation and delivery. Laronde was founded in 2017 by Flagship Labs, the innovation foundry of Flagship Pioneering. The company is rapidly scaling to support the parallel development of multiple programs across many disease areas.
LARONDE
Industry:
Biotechnology Medical Therapeutics
Founded:
2017-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.laronde.bio
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
490 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Nginx Microsoft Exchange Online Organization Schema Office 365 Mail
Similar Organizations
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Vivodyne
Vivodyne develops an automated robotic system that discovers life-changing drugs and cellular therapies.
Current Advisors List
Current Employees Featured
Founder
Investors List
BlackRock
BlackRock investment in Series B - Laronde
Invus
Invus investment in Series B - Laronde
Flagship Pioneering
Flagship Pioneering investment in Series B - Laronde
T. Rowe Price
T. Rowe Price investment in Series B - Laronde
Federated Kaufmann Fund
Federated Kaufmann Fund investment in Series B - Laronde
Longevity Vision Fund
Longevity Vision Fund investment in Series B - Laronde
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series B - Laronde
CPP Investments
CPP Investments investment in Series B - Laronde
Flagship Pioneering
Flagship Pioneering investment in Series A - Laronde
Key Employee Changes
| Date | New article |
|---|---|
| 2022-08-04 | Laronde Appoints John Mendlein as Chief Executive Officer |
Official Site Inspections
http://www.laronde.bio Semrush global rank: 3.28 M Semrush visits lastest month: 4.99 K
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Laronde"
Laronde - Crunchbase Company Profile & Funding
Laronde develops an eRNA-based therapeutic platform that is capable of indicating diverse proteins inside the body. It is persistent, non-immunogenic, allows for repeat dosing, and …See details»
Laronde, Senda Biosciences merge to create new …
Oct 19, 2023 · Flagship Pioneering-launched startups Laronde and Senda Biosciences are merging to form a new biotechnology company called Sail Biomedicines, the companies announced Thursday. The new company said it …See details»
Flagship Pioneering Announces the Merger of Two …
CAMBRIDGE, Mass., Oct. 19, 2023 /PRNewswire/ -- Flagship Pioneering today announced the combination of Laronde and Senda Biosciences to launch Sail Biomedicines, a company pioneering the design...See details»
Laronde banks $440M to ramp up RNA-based meds …
Aug 30, 2021 · Laronde launched out of Flagship Labs this year with a lofty vision: to deliver as many as 100 new RNA medicines over the next 10 years. Now, it’s fueling that goal with a major $440 million...See details»
Laronde - LinkedIn
Laronde is pioneering a platform that offers a completely novel way of modulating human biology. Endless RNA™ (eRNA), is a uniquely engineered RNA that can be programmed to express diverse...See details»
Flagship Pioneering Unveils Laronde to Advance… | Flagship …
Cambridge, Mass., May 10, 2021 – Flagship Pioneering today unveiled Laronde, a platform company developing Endless RNA™ (eRNA), a novel, engineered form of RNA that can be …See details»
Flagship's embattled Laronde sets sail with Senda in …
Oct 19, 2023 · Flagship Pioneering’s Senda Biosciences and Laronde are merging into Sail Biomedicines, a new biotech designed to develop programmable medicines with more than $700 million in its combined...See details»
Laronde merges with another biotech after data integrity issue
Oct 19, 2023 · Now, Laronde is merging with another Flagship company, Senda Biosciences, according to a statement released Thursday. The joint venture will be called Sail …See details»
Laronde Attracts $440M in First External… | Flagship Pioneering
Aug 30, 2021 · Laronde is pioneering a platform that offers a completely novel way of modulating human biology. Endless RNA™ (eRNA), invented at Flagship Labs, is a uniquely engineered …See details»
Laronde Announces New Leadership - Business Wire
May 8, 2023 · SOMERVILLE, Mass.-- ( BUSINESS WIRE )--Laronde, the company pioneering Endless RNA ™ (eRNA) – a novel, engineered form of RNA that can be programmed to express proteins inside the body for...See details»
Laronde Appoints Pablo J. Cagnoni as Chief Executive Officer
Nov 17, 2022 · Laronde is pioneering a platform that offers a completely novel way of modulating human biology. Endless RNA™ (eRNA), invented at Flagship Labs, is a uniquely engineered …See details»
Laronde raises $440 million for its circular eRNA therapies
Aug 30, 2021 · Every month, Laronde’s two manufacturing suites can synthesize 1,000 different eRNAs, which the company can evaluate in laboratory studies, including in animals, in just 8 …See details»
Laronde Expands Board of Directors with Leading Pharmaceutical ...
Nov 1, 2021 · CAMBRIDGE, Mass.-- ( BUSINESS WIRE )--Laronde, the company pioneering Endless RNA™ (eRNA) – a novel, engineered form of RNA that can be programmed to …See details»
Flagship Pioneering Unveils Laronde to Advance Endless RNA™
CAMBRIDGE, Mass., May 10, 2021 /PRNewswire/ -- Flagship Pioneering today unveiled Laronde, a platform company developing Endless RNA™ (eRNA), a novel, engineered form of …See details»
Flagship launches Laronde to develop circular RNA therapies
May 17, 2021 · Flagship Pioneering has launched Laronde to create a new kind of RNA therapy that is circular instead of linear—one it calls endless RNA, or eRNA. Flagship has committed …See details»
Moderna founder launches new biotech, looking to cure diseases …
May 10, 2021 · Laronde comes equipped with $50 million from Flagship Pioneering and a goal to upend how diseases are treated with long-lasting RNA medicines.See details»
Laronde Announces New Leadership | Laronde
Introducing endless RNA (eRNA™) — a powerful new platform that can be programmed to make any therapeutic protein inside the body.See details»
Flagship debuts Laronde to develop RNA-based meds that could …
May 10, 2021 · Laronde—literally “the round” in French—launches with $50 million from Flagship to develop an engineered form of circular RNA that sticks around in the body for a long time, …See details»
Moderna's founder launches Laronde, promising new 'Endless …
2 days ago · Flagship Pioneering, the VC fund run by Moderna’s co-founder Noubar Afeyan has launched a new biotech Laronde, with an ambitious plan to create a new class of drugs based …See details»
Bio - Sandra Laronde
An accomplished arts innovator, multidisciplinary artist and visionary leader, Laronde stands at the forefront of the ongoing Indigenous cultural resurgence of Canada and beyond. Sandra’s …See details»